Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (Weighted Average): 2022-2025

Historic Shares Outstanding (Weighted Average) for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $134.6 million.

  • Prime Medicine's Shares Outstanding (Weighted Average) rose 12.12% to $134.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.6 million, marking a year-over-year increase of 12.12%. This contributed to the annual value of $131.2 million for FY2024, which is 34.77% up from last year.
  • Prime Medicine's Shares Outstanding (Weighted Average) amounted to $134.6 million in Q3 2025, which was up 2.50% from $131.3 million recorded in Q2 2025.
  • Prime Medicine's Shares Outstanding (Weighted Average)'s 5-year high stood at $134.6 million during Q3 2025, with a 5-year trough of $94.3 million in Q2 2022.
  • For the 3-year period, Prime Medicine's Shares Outstanding (Weighted Average) averaged around $116.1 million, with its median value being $120.0 million (2024).
  • Data for Prime Medicine's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 34.77% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Prime Medicine's Shares Outstanding (Weighted Average) stood at $97.2 million in 2022, then grew by 0.12% to $97.3 million in 2023, then spiked by 34.77% to $131.2 million in 2024, then increased by 12.12% to $134.6 million in 2025.
  • Its last three reported values are $134.6 million in Q3 2025, $131.3 million for Q2 2025, and $131.2 million during Q1 2025.